PMID- 28424415
OWN - NLM
STAT- MEDLINE
DCOM- 20180410
LR  - 20221207
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 15
DP  - 2017 Apr 11
TI  - Clinicopathological features and outcome of chronic lymphocytic leukaemia in 
      Chinese patients.
PG  - 25455-25468
LID - 10.18632/oncotarget.16037 [doi]
AB  - Chronic lymphocytic leukaemia (CLL) is uncommon in Chinese population and its 
      biology, genetics and treatment outcome in Chinese patients have not been 
      comprehensively investigated. In this study, we studied the clinicopathological 
      features and outcome of 212 Chinese patients with newly diagnosed CLL in Hong 
      Kong and Singapore. The median age at diagnosis was 64 years. The majority of 
      patients presented with early-stage disease (Binet stage A, 56.1%). Del(13)(q14) 
      was the most frequent abnormality (41.7%) detected by fluorescence in situ 
      hybridization (FISH) analysis. Del(17p) and TP53 gene mutations were detected in 
      7.8% and 8.2% of patients, respectively. MYD88 mutations were found at a higher 
      frequency (11.5%) than expected. CLL with unmutated variable region of the 
      immunoglobulin heavy chain genes (IGHV) occurred in only 31.2% of cases, and was 
      associated with advanced-stage disease (p <0.01) and adverse FISH abnormalities 
      (p<0.01). With a median follow-up of 39 months, the median overall survival (OS) 
      was 108 months. The presence of del(17p) or TP53 mutations was associated with a 
      significantly shorter time to first treatment and an inferior OS (p <0.01). 
      Unmutated IGHV was also associated with a significantly shorter time to treatment 
      (p <0.01). Among patients who required treatment, the median OS and 
      progression-free survival (PFS) were 107 and 23 months, respectively. The 
      presence of del(17p) was associated with a significantly inferior OS and PFS (p 
      <0.01). In summary, Chinese CLL patients had similar genetic aberrations at 
      diagnosis compared with those of Western populations. FISH abnormalities are 
      major factors affecting outcome.
FAU - Chan, Thomas Sau-Yan
AU  - Chan TS
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Lee, Yuh-Shan
AU  - Lee YS
AD  - Department of Haematology, Singapore General Hospital, Outram, Singapore.
FAU - Del Giudice, Ilaria
AU  - Del Giudice I
AD  - Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, 
      Italy.
FAU - Marinelli, Marilisa
AU  - Marinelli M
AD  - Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, 
      Italy.
FAU - Ilari, Caterina
AU  - Ilari C
AD  - Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, 
      Italy.
FAU - Cafforio, Luciana
AU  - Cafforio L
AD  - Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, 
      Italy.
FAU - Guarini, Anna
AU  - Guarini A
AD  - Department of Molecular Medicine, Sapienza University, Rome, Italy.
FAU - Tan, Daryl
AU  - Tan D
AD  - Department of Haematology, Singapore General Hospital, Outram, Singapore.
FAU - Phipps, Colin
AU  - Phipps C
AD  - Department of Haematology, Singapore General Hospital, Outram, Singapore.
FAU - Goh, Yeow-Tee
AU  - Goh YT
AD  - Department of Haematology, Singapore General Hospital, Outram, Singapore.
FAU - Hwang, William
AU  - Hwang W
AD  - Department of Haematology, Singapore General Hospital, Outram, Singapore.
FAU - Goh, Allan Zhi-Kai
AU  - Goh AZ
AD  - Department of Haematology, Singapore General Hospital, Outram, Singapore.
FAU - Siu, Lisa Lai-Ping
AU  - Siu LL
AD  - Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China.
FAU - Wu, Saliangi
AU  - Wu S
AD  - Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China.
FAU - Ha, Chun-Yin
AU  - Ha CY
AD  - Department of Medicine, Tuen Mun Hospital, Hong Kong, China.
FAU - Lin, Shek-Ying
AU  - Lin SY
AD  - Department of Medicine, United Christian Hospital, Hong Kong, China.
FAU - Kwok, Chi-Hang
AU  - Kwok CH
AD  - Department of Medicine, Princess Margaret Hospital, Hong Kong, China.
FAU - Lau, Chi-Kuen
AU  - Lau CK
AD  - Department of Medicine, Tseung Kwan O Hospital, Hong Kong, China.
FAU - Wong, Kit-Fai
AU  - Wong KF
AD  - Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China.
FAU - Foa, Robin
AU  - Foa R
AD  - Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, 
      Italy.
FAU - Kwong, Yok-Lam
AU  - Kwong YL
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Tse, Eric
AU  - Tse E
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - Female
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
PMC - PMC5421943
OTO - NOTNLM
OT  - Chinese
OT  - chronic lymphocytic leukaemia
OT  - clinical outcomes
OT  - pathological characteristics
OT  - prognostication
COIS- CONFLICTS OF INTEREST The authors declare that they have no competing interests.
EDAT- 2017/04/21 06:00
MHDA- 2018/04/11 06:00
PMCR- 2017/04/11
CRDT- 2017/04/21 06:00
PHST- 2016/11/14 00:00 [received]
PHST- 2017/02/13 00:00 [accepted]
PHST- 2017/04/21 06:00 [pubmed]
PHST- 2018/04/11 06:00 [medline]
PHST- 2017/04/21 06:00 [entrez]
PHST- 2017/04/11 00:00 [pmc-release]
AID - 16037 [pii]
AID - 10.18632/oncotarget.16037 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Apr 11;8(15):25455-25468. doi: 10.18632/oncotarget.16037.